Skip to main content
SpringerLink
Log in

Guidelines for Use of Aprotinin with the Ross Procedure

  • Chapter
Cardiac Reconstructions with Allograft Tissues

  • 651 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lemmer JH, Jr., Dilling EW, Morton JR, Rich JB, Robicsek F, Bricker DL, Hantler CB, et al. Aprotonin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996;62:1575–1577.

    Article  Google Scholar 

  2. Levy JF, Pifarre R, Schaff HV, Harrow JC, Albus R, Spiess B, et al. A multicenter, double blind, placebo controlled trial of aprotinin for reducing blood loss and the requirement for donor blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92:2236–2244.

    PubMed  CAS  Google Scholar 

  3. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotonin on need for blood transfusion after repeat open heart surgery. Lancet 1987;2:1289–1291.

    PubMed  CAS  Google Scholar 

  4. Cosgrove DM, Heric L, Lytle BW, Taylor PC, Novoa R, Golding LA, Stewart RW, et al. Aprotonin therapy for reoperative myocardial revascularization: a placebo controlled study. Ann Thorac Surg 1992;54:1031–1038.

    PubMed  Google Scholar 

  5. Sundt TM, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993;55:1418–1424.

    PubMed  Google Scholar 

  6. Westaby S, Forni A, Dunning J, Diannopoulos N, O’Regan D, Drossos G, Pillai R. Aprotinin and bleeding in profoundly hypothermic perfusion. EJCTS 1994;8:82–86.

    CAS  Google Scholar 

  7. Goldstein DJ, DeRosa CM, Mongero LB, Michler RE, Rose EA, Oz NC, Smith CR. Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest. J Thorac Cardiovasc Surg 1995;110:1615–1622.

    PubMed  CAS  Google Scholar 

  8. Regragui IA, Bryan AJ, Izzat MB, Wisheart JD, Hutter JA, Angelini G. Aprotinin use with hypothermic circulatory arrest for aortic valve and thoracic aortic surgery: renal function and early survival. J Heart Valve Dis 1995;4:669–673.

    Google Scholar 

  9. Bidstrup BP, Underwood SR, Sapsford RN. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993;105:147–153.

    PubMed  CAS  Google Scholar 

  10. Kalangos A, Tayyareci G, Pretre R, DiDio P, Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. EJCTS 1994;8:651–656.

    CAS  Google Scholar 

  11. Havel M, Grabenwoger F, Schneider J, Laufer G, Wolenek G, Owen A, Simon P, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing post operative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994;107:807–810.

    PubMed  CAS  Google Scholar 

  12. Lemmer JH, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg 1994;107:543–553.

    PubMed  Google Scholar 

  13. Murkin JM, Lux J, Shannon NA, Guiraudon GM, Menkis AH, McKenzie FN, Novick RJ. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994;107:554–561.

    PubMed  CAS  Google Scholar 

  14. Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, Utretzky G, et al. Analysis of coronary graft patency after aprotinin use: results from the international multicenter aprotinin graft patency experience (image) trial. J Thorac Cardiovasc Surg 1998;116:716–730.

    PubMed  CAS  Google Scholar 

  15. Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite-and kaolin-activated clotting time in heparin-pretreated patients undergoing open heart surgery: a double blind, placebo controlled study. Anesthesiology 1995;83:679–689.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Arthur A. Bert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Bert, A.A. (2005). Guidelines for Use of Aprotinin with the Ross Procedure. In: Cardiac Reconstructions with Allograft Tissues. Springer, New York, NY. https://doi.org/10.1007/0-387-26515-5_43

Download citation

  • DOI: https://doi.org/10.1007/0-387-26515-5_43

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-94962-8

  • Online ISBN: 978-0-387-26515-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation